To evaluate the reproducibility and robustness of our protocol, we applied it to the four most frequent muscular dystrophies, i.e., Duchenne Muscular Dystrophy (DMD, OMIM 310200), Myotonic Dystrophy (DM1, OMIM 160900), Facio Scapulo Humeral Dystrophy (FSHD2, OMIM 158901) and Limb Girdle Muscular Dystrophy 2A (LGMD2A, or LGMDR1, OMIM 253600). This evidence concerns the gene CAPN3 and muscular dystrophy.